AVIR
Atea Pharmaceuticals, Inc.
Key Financials
Operating Income
$-180887000
↑ 6.3%
Revenue
$351.4M
0.0%
EPS (Diluted)
$-1.94
↑ 3.0%
Net Income
$-158349000
↑ 6.0%
Total Assets
$315.2M
↓ 32.2%
Total Liabilities
$39.8M
↑ 54.2%
Cash & Equivalents
$95.7M
↑ 47.9%
Shareholders' Equity
$275.4M
↓ 37.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/12/2026 | View on SEC |
| 8-K | 8/12/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AVIR |
| Company Name | Atea Pharmaceuticals, Inc. |
| CIK | 1593899 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | MA |
| Phone | (857) 284-8891 |